BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Ipsen (IPN.PA) And CNRS Create The "Archi-Pex" Joint Research And Innovation Lab, In Collaboration With The University Of Rennes 1 And CEA 11/20/2014 1:41:55 PM
Ipsen (IPN.PA) And Salk Institute for Biological Studies Renew Their Agreement For Discovery Research In Medical Sciences 11/18/2014 12:57:36 PM
Ipsen (IPN.PA) Announces FDA Approval Of A New Delivery Device For Somatuline® Depot® (Lanreotide) Injection 11/6/2014 11:06:28 AM
Otonomy, Inc. (OTIC) Obtains Rights To Gacyclidine Data From Ipsen (IPN.PA) To Support Development Of OTO-311 As A Treatment For Tinnitus 11/6/2014 11:02:22 AM
Ipsen (IPN.PA): Sales In The 3rd Quarter And First Nine Months Of 2014 10/29/2014 8:55:09 AM
Lexicon Pharmaceuticals, Inc. (LXRX), Ipsen (IPN.PA) Strike Licensing Deal Worth $145 Million 10/22/2014 6:00:45 AM
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014 11:02:52 AM
Aymeric Le Chatelier Joins Ipsen (IPN.PA) As Executive Vice President, Chief Financial Officer 10/10/2014 8:32:34 AM
Susheel Surpal Steps Down As Executive Vice President, Chief Financial Officer Of Ipsen (IPN.PA) To Pursue Other Opportunities 10/2/2014 10:39:22 AM
Ipsen (IPN.PA) Presents Preliminary Results Of Exploratory Proof-Of-Concept Study With Tasquinimod In Four Advanced Tumor Types At The ESMO 2014 Congress 9/29/2014 12:05:48 PM
12345678910...